Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas

Condition(s) studied

Investigational drug(s) / intervention(s)

proteomic profiling: proteomic profiling

Study summary

Distal cholangiocarcinoma and pancreatic adenocarcinoma are aggressive cancers with overlapping diagnostic features, making them challenging to differentiate. Although both require similar surgical treatment, their postoperative chemotherapy regimens differ significantly, with capecitabine used for distal cholangiocarcinoma and modified FOLFIRINOX for pancreatic adenocarcinoma, based on distinct guidelines. In 10-20% of cases, due to their close anatomical proximity, pathologists cannot distinguish between these cancers, leading to diagnostic uncertainty and potential therapeutic missteps. Proteomic profiling, a cutting-edge technique leveraging protein analysis for diagnostic precision, could offer a novel solution to this challenge, although it has yet to be applied in this context

Eligibility

Primary outcome measure(s)

• proteomic signature — baseline
  proteomic signature capable of differentiating cholangiocarcinoma from pancreatic adenocarcinoma through proteomic profiling of surgical specimens

Trial sites (1)

More University Hospital, Bordeaux trials in France

Other trials for the same condition